ABT-301

ABT-301 is a small-molecule drug developed by Anbogen Therapeutics. Its target is Histone deacetylases (HDAC). ClinicalTrials.gov describes the intervention as: ABT-301 is an oral histone deacetylase inhibitor (HDACi) administered in capsule form once daily (QD ±3 hours) or every 12 hours (Q12H ±3 hours, with at least 9 hours between doses) with water in 21-day treatment cycles. In Part 1 (dose-esc. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in colorectal cancer. The largest, NCT07244705, plans to enrol 66 participants with primary completion expected 2028-04. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.